Category - Developments

Developments

Vital Therapies added to NASDAQ biotechnology index

Vital Therapies (NASDAQ:VTL) has been selected for addition to the NASDAQ biotechnology index, effective prior to the opening on Dec. 18. Companies in the index must meet eligibility requirements, including minimum...

December 11, 2017

Developments

Peer-reviewed article further validates Ortho RTi tissue repair

A peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that Ortho Regenerative Technologies’ (CSE:ORTH) Ortho-R hybrid implants release more growth factors and...

December 6, 2017

Developments

NeuroproteXeon additional Phase 2 data published in JACC

Closely-held NeuroproteXeon announced the publication of a second finding from a randomized, controlled Phase 2 trial of inhaled xenon and oxygen, combined with hypothermia, for out-of-hospital cardiac arrest (OHCA)...

November 30, 2017

Developments

Molteni to commercialize Titan Pharma’s Probuphine in Europe

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a binding term sheet with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, giving Molteni an exclusive license to commercialize Probuphine...

November 28, 2017

Developments

Spartan Bioscience launches Legionnaires DNA test

Closely-held Spartan Bioscience has launched the Spartan Legionella Detection System, the first on-site DNA test for Legionella that can detect and quantify Legionella bacteria in 45 minutes. The system consists of a...

November 27, 2017

Developments

EMA accepts Titan’s Probuphine marketing application for review

The European Medicines Agency has accepted for review Titan Pharmaceuticals’ (NASDAQ:TTNP) marketing authorization application (MAA) for Probuphine. The acceptance marks the beginning of the EMA’s regulatory...

November 27, 2017

Developments

BioLight agrees to sell stake in IOPtima

BioLight Life Sciences (TASE:BOLT) and other shareholders of its subsidiary, IOPtima, entered into a binding agreement for the investment and acquisition in stages of IOPtima by Chengdu Kanghong Pharmaceutical Group of...

November 21, 2017

Developments

BiondVax, NIAID in Phase 2 trial of universal flu vaccine

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The study is designed to evaluate...

November 20, 2017

Developments

Oramed to conduct NASH study with oral insulin capsule

Oramed Pharmaceuticals (NASDAQ:ORMP) received approval from Israel’s Ministry of Health to initiate an exploratory clinical study of its oral insulin capsule, ORMD-0801, in patients with nonalcoholic...

November 14, 2017

Developments

Theralase researcher discovers potent anti-cancer drugs

Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry...

November 14, 2017

Category - Developments

Subscribe